Impact of COVID-19 on the Cardiovascular System: A Review

Matsushita, Kensuke; Marchandot, Benjamin; Jesel, Laurence; Ohlmann, Patrick; Morel, Olivier

doi:10.3390/jcm9051407

Cited by 49 publications

(71 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In COVID‐19, cardiovascular complications frequently occur, including arrhythmias, myocarditis, heart failure, and myocardial infarction [29]. All these conditions are negatively affected by sympathetic overactivation and could represent a way through which comorbidity‐induced sympathoactivation may increase COVID‐19 morbidity/mortality.…”

Section: Sympathetic Overactivity May Exert Significant Detrimental Ementioning

confidence: 99%

Sympathetic activation: a potential link between comorbidities and COVID‐19

et al. 2020

View full text Add to dashboard Cite

In coronavirus disease 2019 (COVID‐19), higher morbidity and mortality are associated with age, male gender, and comorbidities, such as chronic lung diseases, cardiovascular pathologies, hypertension, kidney diseases, diabetes mellitus, and obesity. All of the above conditions are characterized by increased sympathetic discharge, which may exert significant detrimental effects on COVID‐19 patients, through actions on the lungs, heart, blood vessels, kidneys, metabolism, and/or immune system. Furthermore, COVID‐19 may also increase sympathetic discharge, through changes in blood gases (chronic intermittent hypoxia, hyperpnea), angiotensin‐converting enzyme (ACE)1/ACE2 imbalance, immune/inflammatory factors, or emotional distress. Nevertheless, the potential role of the sympathetic nervous system has not yet been considered in the pathophysiology of COVID‐19. In our opinion, sympathetic overactivation could represent a so‐far undervalued mechanism for a vicious circle between COVID‐19 and comorbidities.

show abstract

Section: Sympathetic Overactivity May Exert Significant Detrimental Ementioning

confidence: 99%

Sympathetic activation: a potential link between comorbidities and COVID‐19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In December 2019, coronavirus disease 2019 (COVID- 19) infected pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, China with further worldwide transmission to a pandemic outbreak [1][2][3][4][5]. A large cluster of COVID-19 occurred in northeast France as early as mid-February, and a substantial number of critically ill patients started to be transferred to our institution (Nouvel Hôpital Civil, Strasbourg, France) from the beginning of March.…”

Section: Introductionmentioning

confidence: 99%

Clinical features of patients with acute coronary syndrome during the COVID-19 pandemic

Matsushita

Hess

Marchandot

et al. 2020

J Thromb Thrombolysis

Self Cite

View full text Add to dashboard Cite

Although a reduction in hospital admissions of acute coronary syndromes (ACS) patients has been observed globally during the coronavirus disease 2019 (COVID-19) pandemic, clinical features of those patients have not been fully investigated. The aim of the present analysis is to investigate the incidence, clinical presentation, and outcomes of patients with ACS during the COVID-19 pandemic. We performed a retrospective analysis of consecutive patients who were admitted for ACS at our institution between March 1 and April 20, 2020 and compared with the equivalent period in 2019. Admissions for acute myocardial infarction (AMI) reduced by 39.5% in 2020 compared with the equivalent period in 2019. Owing to the emergency medical services (EMS) of our region, all time components of ST-elevated myocardial infarction care were similar during the COVID-19 outbreak as compared with the previous year’s dataset. Among the 106 ACS patients in 2020, 7 patients tested positive for COVID-19. Higher incidence of type 2 myocardial infarction (29% vs. 4%, p = 0.0497) and elevated D-dimer levels (5650 μg/l [interquartile range (IQR) 1905–13,625 μg/l] vs. 400 μg/l [IQR 270–1050 μg/l], p = 0.02) were observed in COVID-19 patients. In sum, a significant reduction in admission for AMI was observed during the COVID-19 pandemic. COVID-19 patients were characterized by elevated D-dimer levels on admission, reflecting enhanced COVID-19 related thrombogenicity. The prehospital evaluation by EMS may have played an important role for the timely revascularization for STEMI patients. Electronic supplementary material The online version of this article (10.1007/s11239-020-02340-z) contains supplementary material, which is available to authorized users.

show abstract

“…Out of these drugs, Enalaprilat has the best binding score from model a. Given reports of the possibility of ACE2 induction being driven by ACE1 inhibition [15] and multiple subsequent reports hinting at benefit from ACE inhibition [16][17][18][19], we were interested to observe ACE2 specificity in comparison to ACE1. For top hits, the binding of ACE2 and ACE1 was compared by calculating the difference in predicted binding (ACE2 binding minus ACE1 binding) using two Fluency models (Table 1).…”

Section: Resultsmentioning

confidence: 99%

Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)

Kim¹,

Zhang²,

Jin³

et al. 2020

J Transl Med

View full text Add to dashboard Cite

Background: The recent global pandemic has placed a high priority on identifying drugs to prevent or lessen clinical infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused by Coronavirus disease-2019 (COVID-19). Methods: We applied two computational approaches to identify potential therapeutics. First, we sought to identify existing FDA approved drugs that could block coronaviruses from entering cells by binding to ACE2 or TMPRSS2 using a high-throughput AI-based binding affinity prediction platform. Second, we sought to identify FDA approved drugs that could attenuate the gene expression patterns induced by coronaviruses, using our Disease Cancelling Technology (DCT) platform. Results: Top results for ACE2 binding iincluded several ACE inhibitors, a beta-lactam antibiotic, two antiviral agents (Fosamprenavir and Emricasan) and glutathione. The platform also assessed specificity for ACE2 over ACE1, important for avoiding counterregulatory effects. Further studies are needed to weigh the benefit of blocking virus entry against potential counterregulatory effects and possible protective effects of ACE2. However, the data herein suggest readily available drugs that warrant experimental evaluation to assess potential benefit. DCT was run on an animal model of SARS-CoV, and ranked compounds by their ability to induce gene expression signals that counteract diseaseassociated signals. Top hits included Vitamin E, ruxolitinib, and glutamine. Glutathione and its precursor glutamine were highly ranked by two independent methods, suggesting both warrant further investigation for potential benefit against SARS-CoV-2. Conclusions: While these findings are not yet ready for clinical translation, this report highlights the potential use of two bioinformatics technologies to rapidly discover existing therapeutic agents that warrant further investigation for established and emerging disease processes.

show abstract

Impact of COVID-19 on the Cardiovascular System: A Review

Cited by 49 publications

References 110 publications

Sympathetic activation: a potential link between comorbidities and COVID‐19

Sympathetic activation: a potential link between comorbidities and COVID‐19

Clinical features of patients with acute coronary syndrome during the COVID-19 pandemic

Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)

Contact Info

Product

Resources

About